Tony Berberabe, MPH

Articles

Temozolomide Trial Shows Improved 5-Year Survival Rates in Anaplastic Glioma

June 4th 2016

Results from a phase III trial investigating the benefit of adjuvant temozolomide in combination with radiation therapy has the potential to be practice changing for a rare type of brain cancer.

Finalists Revealed for the 2016 Giants of Cancer Care Awards

June 3rd 2016

An elite group of finalists have been recognized for their achievements, talent, and the compassionate care they provide to their patients and families in the 2016 Giants of Cancer Care® recognition program.

FDA Approves Radioactive Imaging Agent Axumin in Recurrent Prostate Cancer

May 27th 2016

The radioactive imaging agent, fluciclovine F18 (Axumin), was approved by the FDA for use in positron emission tomography scans in men with suspected recurrence of prostate cancer whose prostate-specific antigen levels rise following prior treatment.

Gene Expression Signature Predicts Hormonal Resistance in Prostate Cancer

May 24th 2016

Using the Decipher Prostate Cancer Classifier assay to predict which patients might respond to hormonal therapy has resulted in the discovery and validation of an adjuvant androgen-deprivation therapy resistance signature.

High Genomic Classifier Score Increases Risk of Dying From Prostate Cancer

May 21st 2016

Results from a study using the Decipher Prostate Cancer Classifier noted that its use added very strong data about the likelihood of patients with prostate cancer dying within 10 years.

ERBB Alteration Linked to Improved PFS With Afatinib in Urothelial Cancer

May 5th 2016

Five of 6 patients with metastatic urothelial cancer and at least 1 of 2 genetic alterations demonstrated a marked improvement in 3-month progression free survival of 6.6 months when given afatinib (Gilotrif), compared with patients who lacked these specific genetic abnormalities.

Acalabrutinib Challenges Ibrutinib in High-Risk CLL Trial

April 22nd 2016

Patients with relapsed chronic lymphocytic leukemia face a difficult treatment journey, but a phase III safety and efficacy trial involving the second-generation Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) will help inform oncologists about whether the emerging agent can offer a greater benefit to patients with high-risk disease over ibrutinib (Imbruvica).

Partner's Buy-In Key to Minneapolis Urology Group's Success

April 10th 2016

At Metro Urology of Minneapolis, urologists are at the forefront of introducing new techniques and technology, especially with respect to advanced prostate cancer care.

Novel Entrectinib Trial Focuses on Gene Rearrangements Across Many Tumor Types

March 30th 2016

Researchers have designed a recently launched clinical study into entrectinib, a first-in-class inhibitor of tropomyosin receptor kinases, as a basket trial in which the drug can be evaluated simultaneously for activity against three gene alterations and multiple tumor types.

Novel Bladder Cancer Strategies Target PD-1/PD-L1 and VEGF Pathways

March 29th 2016

Emerging agents targeting the PD1/PD-L1 pathway and the process of angiogenesis are shaping up to be promising options to break a 30-year drought in new therapies for patients with progressive metastatic urothelial bladder cancer.

Questions Loom Over Androgen-Targeting Strategies in Metastatic Prostate Cancer

March 22nd 2016

Targeting androgen receptor signaling with recently approved agents has improved outcomes for men with metastatic castration-resistant prostate cancer but significant questions linger about how to tackle resistance to the therapies.

Quality of Life Scores Similar in Men Undergoing Active Surveillance Versus Those Without Prostate Cancer

March 14th 2016

Men with low-risk prostate cancer who chose active surveillance (AS) reported a higher quality of life than men who chose direct active treatment such as surgery or radiation.

Pancreatic Cancer Vaccine Makes Progress in Two Late-Stage Trials

March 10th 2016

The novel therapeutic vaccine algenpantucel-L, which is genetically engineered from human cell lines, is being evaluated in two phase III trials in patients with resected pancreatic cancer (IMPRESS) and borderline resectable or locally advanced unresectable pancreatic cancer (PILLAR).

Secondary Cancers Linked to Radiotherapy in Men With Prostate Cancer

March 9th 2016

Men with prostate cancer treated with radiotherapy were at higher risk for developing second malignancies in the bladder, colon, and rectum compared with men who were not exposed to radiotherapy.

Vitamin D Could Serve as Biomarker for Aggressive Prostate Cancer

March 7th 2016

The level of vitamin D in a patient’s blood could serve as a biomarker for an aggressive form of prostate cancer, especially in men who are considering active surveillance for the disease.

Biomarker-Directed Galeterone Explored in Prostate Cancer Trial

February 24th 2016

Galeterone is being explored in the ARMOR 3-SV study, in which men with progressive metastatic disease who have received prior androgen deprivation therapy are randomized to receive either galeterone or enzalutamide.

FDA Agrees to Review Supplemental NDA for Enzalutamide in Metastatic Prostate Cancer

February 23rd 2016

The FDA has accepted, for review, a supplemental new drug application for enzalutamide (Xtandi) capsules in patients with metastatic castration-resistant prostate cancer that includes findings from the head-to-head studies, TERRAIN and STRIVE.

First Urology of Louisville Enjoys Many Firsts in Technology and Research

February 9th 2016

Being the largest private practice urology center in Kentucky has its advantages, said Ganesh Rao, MD, president of First Urology, PSC, in Louisville.

Durvalumab/Tremelimumab Combo Explored in Lung Cancer Trial

February 5th 2016

With the approval of a dual checkpoint blockade treatment in melanoma, researchers hope to have similar success in a phase III trial that combines a PD-L1 inhibitor and CTLA-4 antibody in patients with non–small cell lung cancer.

In a Crowded Field, High-Intensity Focused Ultrasound Stakes a Claim

February 2nd 2016

The landscape for the patient with localized prostate cancer is filled with both new and exciting treatments. With better methods to screen, improved imaging scans to determine physical location and extent of cancer, and even active surveillance, there are many options to consider.

NEXT PAGE
PREVIOUS PAGE
x